目的 探討腎康注射液聯(lián)合替米沙坦和鹽酸貝那普利治療糖尿病腎病的臨床療效。方法 選取2014年1月-2015年10月上海市浦東新區(qū)人民醫(yī)院腎臟內(nèi)科收治的糖尿病腎病患者94例,隨機(jī)分為對照組和治療組,每組各47例。對照組口服鹽酸貝那普利片,10 mg/次,1次/d;同時(shí)口服替米沙坦片,40 mg/次,1次/d。治療組在對照組治療基礎(chǔ)上靜脈滴注腎康注射液,100 mL加入250 mL生理鹽水,1次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效,比較兩組治療前后血肌酐(Scr)、血尿素氮(BUN)、24 h尿蛋白(24 h Upro)、收縮壓(SBP)、舒張壓(DBP)、尿白蛋白排泄率(UAER)、內(nèi)生肌酐清除率(Ccr)、QLQ-C評分、KPS評分和HAD評分的變化情況。結(jié)果 治療后,對照組和治療組的總有效率分別為78.72%、93.62%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患者Scr、BUN、24 h Upro、SBP、DBP、UAER、HAD評分均較同組治療前明顯降低,Ccr、QLQ-C評分、KPS評分較治療前升高,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);治療后治療組Scr、BUN、24 h Upro、UAER、Ccr、HAD評分、QLQ-C評分、KPS評分的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 腎康注射液聯(lián)合替米沙坦和鹽酸貝那普利治療糖尿病腎病具有較好的臨床療效,可有效改善患者的腎功能,提高患者的生活質(zhì)量和活動狀態(tài),有利于患者負(fù)面情緒的緩解,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Shenkang Injection combined with telmisartan and benazepril hydrochloride in treatment of diabetic nephropathy.Methods Patients (94 cases) with diabetic nephropathy in Department of Nephrology of People's Hospital of Pudong New Area in Shanghai from January 2014 to October 2015 were randomly divided into control and treatment groups. Each group had 47 cases. The patients in the control group were poadministered with Benazepril Hydrochloride Tablets, 10 mg/time, once daily, and they were poadministered with Telmisartan Tablets, 40 mg/time, once daily. The patients in the treatment group were ivadministered with Shenkang Injection on the basis of the control group, 100 mL added into 250 mL normal saline, once daily. The patients in two groups were treated for 4 weeks. After treatment, the efficacy was evaluated, and the changes of Scr, BUN, 24 h Upro, SBP, DBP, UAER, Ccr, QLQ-C score, KPS score and HAD score in two groups were compared.Results After treatment, the efficacies in the control and treatment groups were 78.72% and 93.62%, respectively, and there were differences between two groups (P < 0.05). After treatment, Scr, BUN, 24 h Upro, SBP, DBP, UAER, and HAD scores in two group were significantly decreased, and Ccr, QLQ-C scores and KPS scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05).Conclusion Shenkang Injection combined with telmisartan and benazepril hydrochloride has clinical curative effect in treatment of diabetic nephropathy, and can effectively improve the kidney function, and can increase the life quality and active, also can remit negative emotions, which has a certain clinical application value.